SG11201901789WA - Anti-gm-csf antibodies and uses thereof - Google Patents

Anti-gm-csf antibodies and uses thereof

Info

Publication number
SG11201901789WA
SG11201901789WA SG11201901789WA SG11201901789WA SG11201901789WA SG 11201901789W A SG11201901789W A SG 11201901789WA SG 11201901789W A SG11201901789W A SG 11201901789WA SG 11201901789W A SG11201901789W A SG 11201901789WA SG 11201901789W A SG11201901789W A SG 11201901789WA
Authority
SG
Singapore
Prior art keywords
shanghai
road
international
jingke
plaza
Prior art date
Application number
SG11201901789WA
Inventor
Zhengyi Wang
Lei Fang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610831525.9A external-priority patent/CN107840885B/en
Priority claimed from CN201610832677.0A external-priority patent/CN107840886B/en
Application filed by I Mab filed Critical I Mab
Publication of SG11201901789WA publication Critical patent/SG11201901789WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WIPO I PCT omit VIII °nolo III 0111100 oimIE (10) International Publication Number WO 2018/050111 Al (51) International Patent Classification: C07K 16/24 (2006.01) A61P 37/02 (2006.01) C12N 15/13 (2006.01) A61P 35/02 (2006.01) A61K 39/395 (2006.01) A61P 19/02 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). A61P 29/00 (2006.01) A61P 35/00 (2006.01) G01N 33/577 (2006.01) G01N 33/68 (2006.01) Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (21) International Application Number: PCT/CN2017/102057 (22) International Filing Date: 18 September 2017 (18.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610831525.9 19 September 2016 (19.09.2016) CN 201610832677.0 19 September 2016 (19.09.2016) CN (71) Applicant: I-MAB [ /CN]; Suite 219, Building 6, Cham- time Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (72) Inventors: WANG, Zhengyi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). FANG, Lei; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). GUO, Bingshi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). ZANG, Jingwu; Suite 219, Build- ing 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (74) Agent: SHANGHAI BESHINING LAW OFFICE; 21st Floor, SFECO Mansion, 681 Xiaomuqiao Road, Shanghai 200032 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) O O (54) Title: ANTI-GM-CSF ANTIBODIES AND USES THEREOF 00 (57) : Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also pro- O vided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders. C
SG11201901789WA 2016-09-19 2017-09-18 Anti-gm-csf antibodies and uses thereof SG11201901789WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610831525.9A CN107840885B (en) 2016-09-19 2016-09-19 GM-CSF antibodies and uses thereof
CN201610832677.0A CN107840886B (en) 2016-09-19 2016-09-19 GM-CSF antibodies and uses thereof
PCT/CN2017/102057 WO2018050111A1 (en) 2016-09-19 2017-09-18 Anti-gm-csf antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201901789WA true SG11201901789WA (en) 2019-03-28

Family

ID=61618639

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901789WA SG11201901789WA (en) 2016-09-19 2017-09-18 Anti-gm-csf antibodies and uses thereof

Country Status (25)

Country Link
US (3) US10647767B2 (en)
EP (1) EP3328887B1 (en)
JP (1) JP7256116B2 (en)
KR (3) KR20190035790A (en)
CN (1) CN109219616B (en)
AU (1) AU2017328383B2 (en)
BR (1) BR112019005274A2 (en)
CA (1) CA3036509C (en)
CL (1) CL2019000702A1 (en)
CO (1) CO2019002550A2 (en)
DK (1) DK3328887T3 (en)
ES (1) ES2887343T3 (en)
HU (1) HUE056238T2 (en)
IL (1) IL265331B2 (en)
MX (1) MX2019003019A (en)
MY (1) MY190021A (en)
NZ (1) NZ750976A (en)
PE (1) PE20190633A1 (en)
PH (1) PH12019500434A1 (en)
PL (1) PL3328887T3 (en)
PT (1) PT3328887T (en)
SG (1) SG11201901789WA (en)
UA (1) UA126565C2 (en)
WO (1) WO2018050111A1 (en)
ZA (2) ZA201901835B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020034097A1 (en) 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
EP3827016A4 (en) * 2018-10-15 2022-05-04 Elixiron Immunotherapeutics (Hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
JP3876002B2 (en) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト Novel methods for producing anti-human antigen receptors and their use
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
CN1202128C (en) 1998-12-08 2005-05-18 拜奥威神有限公司 Method for reducing immunogenicity of proteins
PT3620171T (en) * 2005-05-18 2022-06-30 Morphosys Ag Anti-gm-csf antibodies and uses therefor
WO2007092939A2 (en) 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
JP2010527939A (en) 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド Neutralizing antibody
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
DK2215119T3 (en) * 2007-11-13 2013-02-04 Evec Inc Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising the same.
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
ES2685895T3 (en) 2008-12-22 2018-10-15 The University Of Melbourne Pain treatment
CN102459340A (en) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011153592A1 (en) 2010-06-10 2011-12-15 Crc For Asthma And Airways Ltd Therapeutic molecules
EP2640747A1 (en) 2010-11-18 2013-09-25 Merck Serono SA Antibody with specificity for gm-csf (ii)
AU2013225812B2 (en) * 2012-03-02 2017-11-30 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
SG11201501595YA (en) 2012-09-20 2015-05-28 Morphosys Ag Treatment for rheumatoid arthritis
AR093297A1 (en) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US20160024200A1 (en) 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
CA2922251C (en) * 2013-08-30 2023-10-17 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CN105031630A (en) * 2014-04-28 2015-11-11 四川大学 Tumor cell vaccine simultaneously secreting PD-1 neutralizing antibody and GM-CSF factor and preparation method thereof

Also Published As

Publication number Publication date
KR102356187B1 (en) 2022-02-08
US20210079085A1 (en) 2021-03-18
CO2019002550A2 (en) 2019-05-21
AU2017328383B2 (en) 2022-10-27
NZ750976A (en) 2023-01-27
EP3328887A4 (en) 2019-04-03
AU2017328383A1 (en) 2019-03-14
UA126565C2 (en) 2022-11-02
ZA201901835B (en) 2021-09-29
IL265331B2 (en) 2024-01-01
HUE056238T2 (en) 2022-02-28
PE20190633A1 (en) 2019-04-26
PL3328887T3 (en) 2021-12-27
CN109219616A (en) 2019-01-15
MY190021A (en) 2022-03-22
EP3328887B1 (en) 2021-08-18
CL2019000702A1 (en) 2019-06-21
IL265331B1 (en) 2023-09-01
PH12019500434A1 (en) 2019-05-20
JP7256116B2 (en) 2023-04-11
MX2019003019A (en) 2019-09-19
CA3036509C (en) 2022-10-25
CA3036509A1 (en) 2018-03-22
KR20210007041A (en) 2021-01-19
KR20190035790A (en) 2019-04-03
US10889641B2 (en) 2021-01-12
ZA202005792B (en) 2021-09-29
JP2019534850A (en) 2019-12-05
ES2887343T3 (en) 2021-12-22
KR20180039742A (en) 2018-04-18
EP3328887A1 (en) 2018-06-06
US10647767B2 (en) 2020-05-12
IL265331A (en) 2019-05-30
PT3328887T (en) 2021-10-19
DK3328887T3 (en) 2021-09-20
US20190002549A1 (en) 2019-01-03
US20180362632A1 (en) 2018-12-20
US11926662B2 (en) 2024-03-12
CN109219616B (en) 2022-10-21
BR112019005274A2 (en) 2019-06-04
KR101953706B1 (en) 2019-03-05
WO2018050111A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811490XA (en) Cd3 binding antibodies
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases